Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicity

Phase 3

Recruiting

Conditions: Gentamicin-induced renal toxicity in hospitalized patients.
Other bacterial diseases
A30-A49

Registration Number: IRCT20161010030246N3

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

The patient's hemodynamic stability
The desire to participate in the study
Gentamicin is given intravenous or intramuscular for at least 1 week at a dose of 5 mg / kg / day or 80-100 mg / TDS
No history of confirmed acute kidney injury.
No history of confirmed chronic kidney injury.
No use of gentamicin by intravenous or muscle in the past 14 days.
No history of confirmed allergic reactions following oral administration of silymarin
No history of confirmed allergic reactions following oral administration of silymarin
Do not receive medications or antioxidant compounds such as vitamin C, vitamin E or vitamin A
Do not receive high-renal toxicity medicines at the same time
Oral tolerance to medications

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of the efficacy of silymarin in preventing renal toxicity due to gentamicin by measuring the malondialdehyde indicator, evaluation of thiol groups, isoprostane and deoxy guanosine, serum creatinine level, serum urea nitrogen, sodium, potassium and magnesium concentration, and calculating sodium, potassium, Magnesium and urea. Timepoint: Sampling from urine and blood (5 ml) of patients before starting the drug (day zero) and on days 1, 2, 3, 5 and 7, treatment with gentamicin. Method of measurement: Measurement of serum and urine levels of electrolytes, urea and creatinine using an autoanalyzer and Isoprostane and desoxy Guanosine indicator will be performed using ELISA and Zell bio kit.

Secondary Outcome Measures